Bioasis Announces Annual General Meeting Results

GUILFORD, Conn.--(BUSINESS WIRE)-- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V: BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, is pleased to announce that all resolutions were passed by the requisite majority at its annual general meeting (“AGM”) held earlier today in Toronto, Ontario.

The four incumbent directors, Dr. Deborah A. Rathjen, John E. Curran, David M. Wurzer and Dr. Mario Saltarelli, were nominated for election and were re-elected by shareholders. Shareholders also approved the re-appointment of Manning Elliott LLP as auditors of the Company for the ensuing year.

About Bioasis

Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The Company maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the company, please visit www.bioasis.us.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Follow us on:

• Twitter:@BioasisUS
• LinkedIn: https://www.linkedin.com/company/bioasis-technologies-inc/

View source version on businesswire.com: https://www.businesswire.com/news/home/20191205005866/en/

On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D., Executive Chair of the Board
[email protected]
+1-203-533-7082

Source: Bioasis Technologies Inc.

You May Also Be Interested In

• T-Mobile Activates T-Satellite and Mobilizes Network Teams as Tropical Storm Lala Approaches Hawaiʻi
• Davis Commodities Limited Announces Receipt of Nasdaq Final Action Letter
• Indiana Flooding: U-Haul Offers Disaster Relief at 34 Stores Statewide